Accessibility Menu
Chugai Pharmaceutical logo

Chugai Pharmaceutical(OTC) CHGCY

Market Cap$72.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)+620%
5 Year+21%
1 Year+3%
1 Month+4%
$21.59
-1.82%
-0.40Today
Chugai Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 21.992026-09-03
Chugai Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.52%USD 21.662026-08-27
1 month+3.73%USD 21.202026-08-04
3 month-4.64%USD 23.062026-06-05
Year to date-16.29%USD 26.272025-12-31
1 year+2.88%USD 21.372025-09-03
3 year+54.18%USD 14.262023-09-01
5 year+20.6%USD 18.232021-09-03
Since inception+620.39%USD 3.052010-11-23

Chugai Pharmaceutical Financials at a Glance

Market Cap

$72.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥1.41T

Net Income (TTM)

¥496.06B

EPS (TTM)

$0.93

P/E Ratio

23.70

Dividend

$0.46

Beta (Volatility)

0.52 (Low)

Price

$21.59

Volume

70,223

Open

$22.53

Previous Close

$21.59

Daily Range

$21.59 - $22.53

52-Week Range

$20.43 - $34.84

Estimated Earnings Date

Oct 23, 2026

CHGCY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd. is a leading pharmaceutical company based in Tokyo, Japan, specializing in the research, development, manufacturing, and sale of innovative drugs. The company operates both domestically and internationally, with a strong presence in Europe, Taiwan, and China.

Products and Services
  • Innovative pharmaceuticals targeting oncology and autoimmune diseases
  • Research and development services for new drug formulations
  • Manufacturing and distribution of high-quality pharmaceutical products
Growth Outlook
  • Revenue increased to JPY 346.08 billion in Q2 2026, up from JPY 327.66 billion in Q1 2026
  • Net income for Q2 2026 reached JPY 117.86 billion, reflecting strong operational efficiency
  • Robust R&D investment of JPY 48.38 billion in Q2 2026 supports future product pipeline
Financial Highlights
  • Trailing twelve-month revenue of JPY 1.4 trillion, indicating consistent growth
  • Net profit margin of 35.1% for Q2 2026, showcasing strong profitability
  • Dividend yield of 3.03% reflects commitment to returning value to shareholders
Chugai Pharmaceutical Co., Ltd. has established itself as a key player in the pharmaceutical industry, focusing on innovative solutions to address unmet medical needs. The company's strong financial performance, highlighted by significant revenue growth and a robust net profit margin, positions it well for future expansion. With a solid commitment to research and development, Chugai is poised to continue delivering value to its stakeholders while contributing to advancements in healthcare. The company's strategic focus on oncology and autoimmune diseases aligns with global healthcare trends, further enhancing its growth potential.
AI Generated • Aug 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7,872

CEO

Osamu Okuda

Website

www.chugai-pharm.co.jp

Headquarters

Tokyo, SH 103-8324, JP

CHGCY Financials

Key Financial Metrics (TTM)

Gross Margin

71.39%

Operating Margin

47.24%

Net Income Margin

35.10%

Return on Equity

24.02%

Return on Capital

30.14%

Return on Assets

19.24%

Earnings Yield

4.22%

Dividend Yield

2.09%

Payout Ratio

94.94%

Stock Overview

Market Cap

$72.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.29B

Volume

70.22K

Avg. Volume

249.82K

Financials (TTM)

Gross Profit

¥1.01T

Operating Income

¥683.08B

EBITDA

¥725.14B

Operating Cash Flow

¥466.19B

Capital Expenditure

-¥50.07B

Free Cash Flow

¥416.12B

Cash & ST Invst.

¥956.22B

Total Debt

¥17.58B

Chugai Pharmaceutical Performance Analysis

Chugai Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31JPY 9,579,323,8285.3%
20232023-12-31JPY 7,903,733,267-17.5%
20242024-12-31JPY 7,727,065,222-2.2%
20252025-12-31JPY 8,408,723,7578.8%
Chugai Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.9%
Q42025-12-3118.4%
Q12026-03-31-18.4%
Q22026-06-305.6%
Chugai Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31JPY 0.873.2%
20232023-12-31JPY 0.70-18.7%
20242024-12-31JPY 0.7810.5%
20252025-12-31JPY 0.8813.5%
Chugai Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.9%
Q42025-12-3129.9%
Q12026-03-31-21.6%
Q22026-06-301.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

¥346.08B

+19.3%

Gross Profit

¥241.10B

+19.4%

Gross Margin

69.67%

N/A

Market Cap

$72.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.19M

N/A

Employees

7,872

N/A

Net Income

¥117.86B

+21.3%

EBITDA

¥162.68B

+18.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

¥956.22B

-6.9%

Total Debt

¥17.58B

+19128.9%

Accounts Receivable

¥379.38B

+19.8%

Inventory

¥315.48B

+33.9%

Long Term Debt

¥0.00

N/A

Short Term Debt

¥0.00

N/A

Return on Assets

19.24%

N/A

Return on Invested Capital

30.83%

N/A

Free Cash Flow

¥121.51B

+31.2%

Operating Cash Flow

¥130.22B

+9.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MKGAFMerck KGaA
$159.12-4.49%
MKKGYMerck KGaA
$31.51-1.84%
IPSEYIpsen S.A.
$49.15+0.00%
SOAGYSartorius Aktiengesellschaft
$55.04-3.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CHGCY

What is the current price of Chugai Pharmaceutical?

Chugai Pharmaceutical is trading at $21.59 per share.

What is the 52-week range for Chugai Pharmaceutical?

Over the past 52 weeks, Chugai Pharmaceutical has traded between $20.43 and $34.84.

How much debt does Chugai Pharmaceutical have?

As of the most recent reporting period, Chugai Pharmaceutical reported total debt of ¥108.86M.

How much cash does Chugai Pharmaceutical have on hand?

Chugai Pharmaceutical reported ¥2.40B in cash and cash equivalents in its most recent financial results.

What is Chugai Pharmaceutical’s dividend yield?

Chugai Pharmaceutical currently has a dividend yield of 2.09%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services